2002•Zhongguo yaofangRequires access

A Comprison of Cost-effectiveness Between Interferon α-2b and Lamivudine in Treating Chronic Hepatitis B

Xiaoguang Ye

Abstract

OBJECTIVE:To compare the therapeutic effects,adverse reactions and the costs between Interferon α-2b and Lamivudine in the treatment of chronic hepatitis B METHODS:Using pharmacoeconomic cost-effectiveness analysis,Lamivudine was compared with Interferon α-2b in the treatment of 100 patients with chronic hepatitis B(divided into two groups) RESULTS:After treatment,the effective rates of Interferon α-2b and Lamivudine were 58 00% and 62 00% respec_tively(P0 05),the cost-effectiveness ratios were 762 49 and 111 85 respectively(P0 01) CONCLUSION:Both of Inter_feron α-2b and Lamivudine can effectively treat chronic hepatitis B,the cost-effectiveness ratio of Lamivudine is superior to that of Interferon α-2b

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Lamivudine, Medicine, Chronic hepatitis, Interferon, Interferon alfa, Hepatitis B, Alpha interferon, Adverse effect